Patients with positive LC3 expression in both the HCC and ANT tissues (+/+) had the best survival rates, and their 1-, 3-, 5- and 7-year overall survival rates were 97.4%, 79.2%, 70.2% and 37.8%, respectively (Fig 3). Here, MAP1LC3A is linked to hepatocellular carcinoma.